In a patient with a recent deep vein thrombosis on apixaban (Eliquis), how should the apixaban be held and resumed around a left‑heart catheterization, and is any bridging anticoagulation indicated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Perioperative Management of Apixaban for Left Heart Catheterization in a Patient with Recent DVT

For left heart catheterization in a patient on apixaban for recent DVT, hold apixaban for 24-48 hours before the procedure (24 hours for radial access, 48 hours for femoral access), and do not use bridging anticoagulation. Resume apixaban 24 hours after the procedure once adequate hemostasis is established 1.

Pre-Procedure Management

Timing of Apixaban Interruption

The approach depends on vascular access site:

  • Radial access (preferred): Hold apixaban for 24 hours before catheterization 2
  • Femoral access: Hold apixaban for 48 hours before catheterization 2, 1

The FDA label explicitly states that apixaban should be discontinued at least 24 hours prior to procedures with low bleeding risk (where bleeding would be non-critical and easily controlled) and at least 48 hours prior to procedures with moderate or high bleeding risk 1. Left heart catheterization falls into the moderate bleeding risk category, with the specific timing modified by access site.

No Bridging Required

Bridging anticoagulation is not indicated for DOACs like apixaban 2, 1. The 2021 ACC Expert Consensus explicitly states: "For those on a DOAC, there is likely no value in bridging, particularly with LMWH because it has similar pharmacokinetic properties to DOAC" 2. The FDA label reinforces this: "Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required" 1.

This represents a critical distinction from warfarin management, where bridging may be considered in high-risk patients. The short half-life and predictable pharmacokinetics of apixaban eliminate the need for parenteral overlap.

Procedural Considerations

Access Site Selection

Strongly prefer radial access to minimize bleeding risk 2. This allows for:

  • Shorter pre-procedure interruption period (24 vs 48 hours)
  • Lower bleeding complications
  • Earlier resumption of anticoagulation

Crossover to femoral access occurs in only 5-10% of cases but requires the longer 48-hour interruption window 2.

Renal Function Considerations

While the evidence provided focuses on standard dosing, verify the patient's creatinine clearance. The interruption intervals assume normal to moderately impaired renal function (CrCl ≥30 mL/min). For severe renal impairment (CrCl 15-29 mL/min), longer interruption periods may be needed 2.

Post-Procedure Management

Resumption of Apixaban

Resume apixaban approximately 24 hours after the procedure once adequate hemostasis is confirmed 3, 1. The 2022 CHEST guidelines specify that DOACs can be resumed 24 hours after low-to-moderate bleeding risk procedures 3.

Key assessment points before resumption:

  • Access site hemostasis is critical - ensure no active bleeding or hematoma expansion
  • Verify stable hemodynamics
  • Confirm no procedural complications requiring extended anticoagulation hold

Thrombosis Risk in Recent DVT

Given this patient has a recent DVT, the thrombotic risk during the brief interruption period is relevant but manageable. The evidence shows that even in high-risk scenarios, the short interruption period with DOACs (24-48 hours) does not require bridging 2, 3. The patient's DVT is being actively treated with therapeutic-dose apixaban (likely 10 mg twice daily for first 7 days, then 5 mg twice daily), which will resume promptly post-procedure.

Common Pitfalls to Avoid

  1. Do not bridge with LMWH or heparin - This increases bleeding risk without reducing thrombotic events in DOAC patients 2, 1

  2. Do not hold apixaban longer than necessary - Extended interruption increases thrombotic risk without additional bleeding benefit

  3. Do not resume apixaban too early - Wait for confirmed hemostasis, particularly at femoral access sites

  4. Do not confuse DOAC management with warfarin protocols - The pharmacokinetics are fundamentally different

  5. Verify the patient's current apixaban dose - Recent DVT patients should be on treatment doses (5-10 mg twice daily), not the reduced 2.5 mg twice daily dose used for extended prophylaxis

Algorithm Summary

Pre-procedure:

  • Radial access planned → Hold apixaban 24 hours before
  • Femoral access planned → Hold apixaban 48 hours before
  • No bridging anticoagulation

Post-procedure:

  • Assess hemostasis at 24 hours
  • If adequate → Resume apixaban at usual dose
  • Continue twice-daily dosing schedule

References

Related Questions

What is the appropriate apixaban (Eliquis) dosing regimen for treating deep vein thrombosis (DVT)?
In a 74-year-old bedridden woman with a prior history of deep vein thrombosis treated with apixaban (Eliquis) for 7 months and chronic residual thrombosis, and a current duplex ultrasound showing no acute DVT, should anticoagulation be restarted?
What is the recommended dosing regimen of apixaban for treatment and prophylaxis of venous thromboembolism in adults, including adjustments for age, weight, and renal function?
In a 75-year-old male with a mechanical aortic valve replacement on warfarin (target INR 2.5–3.5), hypertension, and dyslipidemia, should I proceed with elective cystoscopy while maintaining therapeutic anticoagulation, or is bridging or holding warfarin required?
For a patient on apixaban (Eliquis), should I give only an apixaban dose as a bridge instead of therapeutic enoxaparin (Lovenox) before left‑heart catheterization?
What is the appropriate treatment for scalp psoriasis in a 40-year-old female with a five-year history, and should baseline laboratory tests be obtained?
What is the appropriate bridging regimen with enoxaparin (Lovenox) for a patient stopping warfarin before a left heart catheterization, including dosing, timing, and renal adjustments?
Should I continue the current regimen of risperidone 0.5 mg in the morning and 1 mg at bedtime, Vyvanse (lisdexamfetamine) 20 mg daily, lamotrigine 75 mg daily, and trazodone at night, and what monitoring is required?
What is the appropriate workup for a patient with chronic pericardial effusion?
In which medical conditions is triptan use contraindicated for a patient on two antihypertensive medications, with coronary artery disease and prior stent placement, stage 4 chronic kidney disease, and type 2 diabetes mellitus with an A1c ≥ 7.5%?
What is the recommended initial treatment for scalp psoriasis in a patient who has never used therapy before?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.